Review of depot aripiprazole for schizophrenia

Farha Bilal Motiwala
Kim Stasia Siscoe
Rif S El-Mallakh
Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA

Abstract: Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will be available soon. A review of all publically available information on depot aripiprazole as of November 2012 was performed. One peer-reviewed study on depot aripiprazole is published, and the remainder of the data were presented at international scientific meetings. Depot aripiprazole appears to be both safe and effective in the long-term treatment of schizophrenia.

Keywords: aripiprazole, schizophrenia, depot, long-acting injectable, psychosis, treatment

Introduction

Schizophrenia is a chronic and debilitating mental illness that requires lifetime management with medication to prevent decompensation and worsening of symptoms over time. Nonadherence with antipsychotic medication is associated with an overall poor prognosis. In addition to increased likelihood of recurrence of psychosis and rehospitalization, patients can experience worsened medical outcomes. Across both first-generation and second-generation antipsychotics, poor adherence is observed in many patients, with estimates of 28.8%–80% of patients being nonadherent with antipsychotic medication. Adherence is minimally better with oral second-generation antipsychotics (SGA) at 54.9% versus 50.1% for first-generation antipsychotics. Several factors lead to nonadherence, including poor insight, coexistent substance-related issues, lack of education and awareness about the illness, stigma, unrealistic expectation for treatment response, adverse consequences of medications, low rate of acceptance of illness, and cognitive disorders. Many interventions have been tried to improve adherence. These include specific treatments such as electronic reminders, interventions that are tailored to the patient, focusing on patient insight, improving oversight by friends or relatives, or focusing on the relationship between the patient and provider. From a medication stand point, long-acting injectable (LAI) antipsychotics are frequently seen as an intervention to improve adherence.

LAIs are in reality a form of supervision of medication administration. Forced treatment, in and of itself, does not improve outcome; however, supervised administration of medication in a trusting relationship can be very effective. In this regard, LAI are nearly universally associated with better outcome when compared with oral medications.
Treatment of schizophrenia patients with depot injections is infrequent worldwide, constituting less than 20% of outpatients. Its use is more common in Denmark, the United Kingdom, and Sweden, while the United States and France have lower rates. Less than one third of psychiatrists offer a depot option to their patients. The leading reason for this is the erroneous impression that patients are adherent with oral medication. The hesitancy to suggest depot medications is in opposition to the data that patients and their families generally have positive attitudes towards depot formulations with many patients preferring the depot form. SGAs are generally preferred by clinicians because of better adherence and better psychosocial outcomes. While the superiority of SGAs has recently been challenged, they remain the preferred class of antipsychotic medications in the management of schizophrenia. Furthermore, despite their upfront higher cost, SGAs can offer cost savings to the health care system. For example, LAI risperidone saves over US$8,000/patient annually in health care costs compared with LAI haloperidol.

Among the SGAs, aripiprazole is considered atypical. Aripiprazole has a unique receptor profile as a partial agonist at the D2 receptor, resulting in fewer extrapyramidal symptoms while still controlling psychotic symptoms. It is also a partial agonist at the 5HT1A receptor and a 5HT2A antagonist. It is the only SGA with greater affinity at the D2 receptor compared with the 5HT2A receptor. In addition, aripiprazole is thought to have a favorable metabolic profile with reduced weight gain and reduced propensity to increase lipids compared with other SGAs. This results in significant reductions in the incidence of diabetes and myocardial infarctions, and consequent savings in cost of total health care (nearly £4 million/year in the United Kingdom), compared with standard of care treatments. Currently, aripiprazole is available as an oral daily medication (also available are oral disintegrating tablets, liquid), as well as a rapidly acting intramuscular injectable for management of acute agitation associated with schizophrenia. Oral aripiprazole offers good tolerability and efficacy for chronic use and thus a depot formulation would be expected to be desirable.

Materials and methods
Searches utilizing the search terms “aripiprazole”, “depot”, and/or “long-acting injectable” in PubMed and Google Scholar resulted in one paper that dealt with LAI aripiprazole. There were no other studies, including no case reports, case series, open studies, or preclinical studies. The one published study was a placebo-controlled, randomized, multiple-site study examining the utility and safety of LAI aripiprazole in relapse prevention in stable patients with schizophrenia. To supplement this one study, data that had been presented previously in poster form at peer-reviewed international professional meetings as of November 2012 were obtained from Otsuka Pharmaceuticals, and included.

Results
Aripiprazole was studied for use as a monthly intramuscular injection. The depot formulation is a lyophilized (cryodesiccated or freeze-dried) powder reconstituted with water, which is then injected into a large muscle. No modification of the aripiprazole molecule was done to develop the long-acting formulation of this medication. With steady absorption from the muscle, plasma levels reach levels similar to that of the hypothesized therapeutic doses of oral aripiprazole. It took approximately 2 months for intramuscular aripiprazole to reach steady state, but mean plasma levels were similar to oral aripiprazole administration within 2 weeks. The half-life of LAI aripiprazole is 46.5 days for a 400 mg dose and 29.9 days for a 300 mg dose, allowing for a once-monthly injection.

One randomized, controlled study of LAI aripiprazole has been published. This study was conducted in 108 centers located throughout the world from July 2008 through February 2011. Subjects had to have schizophrenia and be stable for 4 weeks on oral aripiprazole to qualify for the study. Stability was defined as being an outpatient, having a Positive and Negative Symptom Scale (PANSS) score of <81, no specific psychotic symptom with a PANSS >4, a Clinical Global Impression score ≤4, and absence of significant suicidality.

Of 1,025 subjects who underwent screening, 843 qualified for the study. Once all patients were converted to oral aripiprazole via cross titration, patients were stabilized on open-label oral aripiprazole monotherapy 10–30 mg daily for 4 consecutive weeks. Patients who met the criteria for stabilization were then stabilized on open-label LAI aripiprazole. Concurrent with the first injection of LAI aripiprazole, oral aripiprazole was continued for 2 weeks. Subjects who remained stable consistently for at least 3 months on depot aripiprazole were randomized into the study in a 2:1 active to placebo ratio, with a total of 403 patients reaching the double-blind randomization phase. Injection of LAI aripiprazole was started at 400 mg intramuscularly independent of oral dose, with the potential to reduce the dose to 300 mg intramuscularly if patients were experiencing adverse effects. During the double-blind phase, 96.3% of the patients remained on 400 mg.
The study was designed to go for 52 weeks, with two predetermined interim analyses, the first after a total of 64 subjects met criteria for recurrence. The interim analysis demonstrated that the active drug was significantly different from placebo, without any overt safety concerns, and the study was stopped early with 58.8% of subjects discontinuing due to sponsor discontinuation.\(^3\)

The primary outcome in the study was recurrence or “relapse”, that was defined in one of four ways: worsening as defined by a score ≥5 on the Clinical Global Impression scale,\(^5\) a collective increase of 4 points in core psychotic symptoms, or an individual increase of two or more in these core psychotic symptoms (on the PANSS\(^6\) including disorganized thoughts, paranoid behavior, hallucinations, or bizarre thoughts/behavior), aggravation of psychotic illness leading to hospital admission, or destructive injury to self, others, or property.

The mean age of the subjects was 40.1 years and 41.7 years for the aripiprazole and placebo groups, respectively. Aripiprazole depot intramuscular injection significantly extended the duration to relapse/recurrence (Figure 1). Of the 80 subjects who experienced a recurrence, 27 were receiving aripiprazole (or 10% of 269 on aripiprazole), and 53 were on placebo (or 39.6% or 134 subjects on placebo).\(^6\) The hazard ratio was calculated at 5.03 (confidence interval 3.15–8.02), meaning placebo-treated subjects were over five times more likely to experience a recurrence (>500% increased risk). The duration to termination of treatment as a result of all adverse events led to termination of the study was significantly lengthened with use of aripiprazole depot, with a termination rate of 24.9% as compared with placebo treatment, which had a 54.5% termination rate.

The actual change in symptomatic level was significantly greater in placebo-treated subjects prior to withdrawal from the study (Figure 2). Placebo-treated subjects experienced a mean 11.6 point increase in total PANSS score, compared with LAI aripiprazole-treated subjects with a mean 1.4 point increase (\(P = 0.0001\)). This difference in PANSS score between the two groups was evident by the second week and persisted throughout the study (Figure 2). Aggression was less common in aripiprazole-treated subjects (3.7%, \(n = 1/27\)) than in placebo-treated subjects (7.5%, \(n = 4/53\)).

Adverse events were relatively uncommon in both active-treated and placebo-treated subjects (Table 1). Adverse events occurring during the initial LAI aripiprazole stabilization period were very similar to those shown in Table 1 of the Kane paper on aripiprazole-treated subjects.\(^6\) Nearly all adverse events were mild to moderate. The only severe adverse events dealt with worsening psychosis, which involved 2.2% of aripiprazole-treated subjects and 4.5% of placebo-treated subjects. Adverse events led to termination in 7.1% (19 of 269) of LAI aripiprazole-treated subjects and 13.4% (18 of 134) of placebo-treated individuals.\(^6,7\)

Pain at the injection site was uncommon (Table 1), and severity was measured by a 100 point visual analog scale; the actual severity was 5.1, declining to 4.0 in aripiprazole-treated subjects, and 5.1 declining to 4.9 in the placebo group.\(^6,7\) Extrapyramidal symptoms were measured using the Abnormal Involuntary Movement Scale,\(^5\) parkinsonism was measured with the Simpson Angus Scale,\(^5\) and akathisia

---

**Figure 1** Time to discontinuation from the study for “impending relapse” (see text for definition) in depot aripiprazole-treated and vehicle-treated subjects.


**Abbreviation:** IM, intramuscular.
Extrapyramidal symptoms were reported more in patients receiving active intramuscular aripiprazole (14.9%) than in patients receiving placebo (9.7%). Measured akathisia was not different between the groups (5.6% and 6.0%, for the patients on aripiprazole depot injection and placebo, respectively). Parkinsonism with tremor was the most commonly reported adverse event at 8.2% for subjects in the aripiprazole group in comparison with 3.0% in the placebo group. However, no significant differences were observed in any of the three extrapyramidal symptom scales between LAI aripiprazole and placebo.

Weight change was not different between the two groups after randomization, with the LAI aripiprazole patients losing a mean of 0.2 kg, and the placebo-treated patients losing a mean of 0.4 kg ($P = 0.812$). A clinically relevant increase in weight (>7% from baseline) was experienced by 6.4% of LAI aripiprazole-treated subjects, and 5.2% of placebo-treated subjects.

Two people died during the study, one due to coronary artery insufficiency during the intramuscular aripiprazole stabilization period and one due to pancreatic carcinoma during the double-blind treatment phase.

In addition to having significant efficacy and a very good safety profile, LAI aripiprazole was also well received by the patients. Acceptance, as measured by the Drug Attitude Inventory, was quite high (score 21.1 versus placebo at 22.2). This was reflected in a Medication Adherence Questionnaire score of 0 to 1, and a final Patient Satisfaction with Medication Questionnaire score of 86.2% in aripiprazole-treated patients versus 85.7% in placebo-treated subjects.

**Table 1** Common adverse events occurring in the double-blind portion of the study

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>LAI aripiprazole (%)</th>
<th>Placebo n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insomnia</td>
<td>27 (10.0)</td>
<td>12 (9.0)</td>
</tr>
<tr>
<td>Increased weight</td>
<td>26 (9.7)</td>
<td>13 (9.7)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>16 (5.9)</td>
<td>10 (7.5)</td>
</tr>
<tr>
<td>Headache</td>
<td>16 (5.9)</td>
<td>7 (5.2)</td>
</tr>
<tr>
<td>Tremor</td>
<td>16 (5.9)</td>
<td>7 (5.2)</td>
</tr>
<tr>
<td>Akathisia</td>
<td>15 (5.6)</td>
<td>8 (6.0)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>10 (3.7)</td>
<td>7 (5.2)</td>
</tr>
<tr>
<td>Worsening psychosis</td>
<td>8 (3.0)</td>
<td>9 (6.7)</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>8 (3.0)</td>
<td>5 (3.7)</td>
</tr>
<tr>
<td>Any adverse events</td>
<td>170 (63.2)</td>
<td>83 (61.9)</td>
</tr>
</tbody>
</table>

Performance scale,\textsuperscript{64} did not change compared with baseline in aripiprazole-treated patients, but declined significantly in placebo-treated patients.\textsuperscript{65}

How would clinicians use, and what could one expect using, aripiprazole intramuscular depot injection in clinical practice? Based on this study, an oral trial and cross taper of the medication should be done prior to initiation of a monthly injection to stabilize symptoms. For the first 2 weeks of the initial depot injection, oral aripiprazole should be continued to allow adequate time for the intramuscular medication to reach adequate plasma concentrations, which we know can take approximately 6–12 days.\textsuperscript{46,55} Injections can then be given monthly without any oral supplementation of the medication based on the half-life of the depot formulation of 46.5 days and 29.9 days for the 400 mg and 300 mg doses, respectively. Providers could expect to see a similar effect on PANSS reduction as the oral formulation and a low rate of recurrence.\textsuperscript{66} Providers could also expect a good patient attitude towards this medication since patients assigned to the LAI formulation were very satisfied with their treatment.

Overall, these data suggest that LAI aripiprazole will be a useful clinical tool when it becomes available. Aripiprazole has many unique and beneficial actions, and the initial data suggest that these will be preserved in the LAI formulation, with the additional benefit of guaranteed medication administration.

 Disclosure

The authors report no conflicts of interest in this work.

References


